We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App





Abbott Showcases Next-Generation Alinity Family of Systems at AACC 2020 Virtual Event

By LabMedica International staff writers
Posted on 15 Dec 2020
Print article
Image: Alinity Family of Systems (Photo courtesy of Abbott)
Image: Alinity Family of Systems (Photo courtesy of Abbott)
Abbott (Lake Forest, IL, USA) showcased leading-edge technology at its virtual booth at 2020 AACC Annual Scientific Meeting with demonstrations of the company’s innovative systems, automation and informatics.

At the all virtual 2020 AACC held on December 13-17, Abbott demonstrated its next-generation Alinity family of systems across key laboratory disciplines designed to simplify diagnostics and help deliver results that drive better patient outcomes. Attendees to Abbott’s virtual booth experienced the company’s Alinity ci-series integrated clinical chemistry and immunoassay system, the Alinity h-series integrated hematology system and the Alinity m molecular system.

The Alinity series helps to easily adapt to the unpredictability of changing laboratory volume with scalable systems and multiple track connectivity options across Alinity platforms. The flexible, scalable systems allow easy addition of modules as lab volume grows over time, without having to replace any system. And with open automation and IT connectivity options such as Instrument Manager and AlinIQ BIS, a personalized solution can be designed for the entire laboratory. All this helps labs respond to the changing needs of the market and the community.

Alinity leverages powerful technology to redefine and improve operational productivity in the laboratory. Alinity allows users to more efficiently and effectively address limited space and increasing demand in their laboratory. Alinity has been designed to maximize the throughput in a more compact footprint. Additionally, Alinity allows staff more walkaway time, so they can focus on other critical tasks.

Alinity helps labs continually provide consistent, high-quality service and results through error-proof design elements and proven technology that minimize the frustration of repeat testing, system downtime, and medical errors. Additionally, labs can rely on Abbott’s high-quality assays with proven technology harmonized to CLSI guidelines, ensuring clear performance parameter definitions. And with predictive system monitoring through AlinIQ Always On, Abbott’s professional services can proactively monitor the health of the systems and help labs avoid unexpected downtime.


New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.